The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Skuland T, Fosslie M, Khodeer S, Alemu EA, Johansen JV, Indahl M, Castroviejo BC, Li Y, Lerdrup M, Dahl JA, Fedorcsak PZ, Greggains GD(2025) Broad H3K4me3 domains support oocyte genome silencing and maturation but are dispensable for repression in early embryos Development, 152(21) DOI 10.1242/dev.204638, PubMed 41143332
Stangeland H, Wentzel-Larsen T, Stensland SØ(2025) Prevalence and risk of psychiatric disorders in young people: prospective cohort study exploring the role of childhood trauma (the HUNT study): commentary, Stangeland et al Br J Psychiatry, 1-2(in press) DOI 10.1192/bjp.2025.10437, PubMed 41133349
Brandtzæg KH, von der Lippe C, Vestengen IK, Holtan JP, Winge MI, Rustad CF, Bergersen TK, Sigurdardottir S, Sjursen W, Gjersvik P, Hortemo KH(2025) Clinical and genetic findings in 103 individuals with basal cell naevus syndrome in Norway Br J Dermatol(in press) DOI 10.1093/bjd/ljaf413, PubMed 41129277